Hepatocellular carcinoma in patients with chronic hepatitis C and cirrhosis in Denmark: A nationwide cohort study

Hallager, Sofie; Ladelund, Steen; Kjær, Mette; Madsen, Lone Galmstrup; Belard, Erika; Laursen, Alex Lund; Gerstoft, Jan; Røge, Birgit Thorup; Grønbæk, K.; Krarup, Henrik; Christensen, Peer Brehm; Weis, Nina

doi:10.1111/jvh.12764

Cited by 7 publications

(6 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cohort studies in both Denmark and the US examining the progression of HCC over a 12-year and 6-year period, respectively, both showed an increased incidence of HCC over time. 20,21 However, it cannot be determined whether this was related to an increase in the prevalence of liver diseases, or an awareness of HCC screening in clinical practice. The increased incidence of HCC has escalated the importance of examining the likelihood of survival and potential mitigating factors.…”

Section: In Ciden Ce and Surveill An Cementioning

confidence: 99%

“…Projections and determining the odds of survival are important in the management and treatment of patients with HCC. Cohort studies in both Denmark and the US examining the progression of HCC over a 12‐year and 6‐year period, respectively, both showed an increased incidence of HCC over time 20,21 . However, it cannot be determined whether this was related to an increase in the prevalence of liver diseases, or an awareness of HCC screening in clinical practice.…”

Section: Incidence and Surveillancementioning

confidence: 99%

See 1 more Smart Citation

Real‐world evidence in hepatocellular carcinoma

Mospan

Morris

Fried

2021

Liver International

View full text Add to dashboard Cite

Real‐world evidence includes all health‐related information, such as electronic health records, insurance claims, pharmacy records and wearables that are obtained outside of clinical trials. These data can provide critical insights into the natural history of disease and evaluate the safety and effectiveness of treatment regimens used in clinical practice. Real‐world data have been applied to varying degrees by global regulatory agencies to inform and expedite many phases of drug development and help refine the use of therapeutic regimens after marketing, especially in populations that are under‐represented in registration trials. For the management of hepatocellular carcinoma, early detection provides the best chance for curative therapies, whose success has been evaluated in numerous cohorts. The availability of novel systemic therapies, including kinase inhibitors and immunotherapies, has provided new treatment options and improved survival in patients with advanced stage hepatocellular carcinoma. Real‐world longitudinal observational studies can help understand the long‐term safety and effectiveness of these agents.

show abstract

Section: In Ciden Ce and Surveill An Cementioning

confidence: 99%

Section: Incidence and Surveillancementioning

confidence: 99%

Real‐world evidence in hepatocellular carcinoma

Mospan

Morris

Fried

2021

Liver International

View full text Add to dashboard Cite

show abstract

“…The incidence of HCC has been on the rise in the United States and around the world [ 59 , 60 ]. Genotype 3 has been associated with significantly higher rates of HCC relative to other genotypes [ 61 ].…”

Section: Clinical Featuresmentioning

confidence: 99%

Hepatitis C virus genotype 3: clinical features, current and emerging viral inhibitors, future challenges

Shahnazarian¹,

Ramai²,

Reddy³

et al. 2018

aog

View full text Add to dashboard Cite

Hepatitis C virus (HCV) represents a global burden on healthcare that affects over 150 million people worldwide. In the past, HCV genotype 3 was considered difficult to treat relative to other genotypes. Genotype 3 has been associated with a higher rate of complications, including fatty liver disease, fibrosis, hepatocellular carcinoma and mortality. However, with the advent of first- and second-generation direct-acting antivirals, genotype 3 can be treated effectively. Additionally, these new drugs are well tolerated by patients and have significantly fewer side effects compared to ribavirin and interferon-based regimens. However, while great strides have been made in overcoming biological barriers, our next challenge lies in overcoming economic and financial obstacles if we are to eradicate HCV genotype 3. Herein, we review the clinical features associated with HCV genotype 3, current and emerging treatment regimens, and challenges associated with treatment.

show abstract

“…7 Although serum alpha-fetoprotein (AFP) is regarded as the International Journal of General Medicine 2022:15 1365-1380 diagnostic and prognostic factor for HCC patients, it is always affected by side diseases, such as chronic hepatitis, cirrhosis and stetosis. [8][9][10] On the other hand, up to 40% of HCC patients are AFP negative. 11,12 Therefore, it is necessary to study new biomarkers to illustrate the prognosis of HCC.…”

Section: Introductionmentioning

confidence: 99%

The Mechanism and Prognostic Value of DNA Polymerase δ Subunits in Hepatocellular Carcinoma: Implications for Precision Therapy

Wang¹,

Zhang²,

Xu³

et al. 2022

IJGM

View full text Add to dashboard Cite

Polymerase δ (POLD) proteins is a pivotal B-family DNA polymerase in the process of genome replication and repair and are comprised of POLD1-4. The predictive value of POLDs in hepatocellular carcinoma (HCC) has not been evaluated until now. Patients and Methods: A total of 369 hepatocellular carcinoma samples and 50 adjacent normal samples were enrolled from the TCGA-LIHC database, and the GSE10186 database was also used. Transcription, methylation and genetic alteration status of HCC patients were evaluated by GEPIA, Kaplan-Meier plotter, cBioPortal, MethHC, MethSurv. SurvExpress was employed to generate the overall prognosis prediction signature of POLDs. POLDs coexpressed genes were explored and enriched in potential pathways. K-M curves were generated to compare the different survival results in different groups, while ROC curves were used to validate the efficiency of the POLD signature. Results: All four POLD subunits were highly expressed in HCC tumor tissues. POLD1-3 and increased mRNA levels were also positively associated with advanced tumor stage and OS prognosis. Methylation in the promoter of POLDs affects mRNA expression and OS, especially for some specific CpG sites. Meanwhile, POLDs could preferably predict the prognosis for patients who suffered from a high gene mutation burden. We evaluated the combined prognostic predictive value of four POLD subunits in both the TCGA-LIHC and GSE10186 databases and recognized the statistically significant HR of the high-risk group, along with the reliable predictive value. The coexpressed gene sets and annotation results showed that the POLD coexpressed genes were mostly associated with DNA repair and cell cycle regulation pathways. Conclusion: POLD is an essential predictive factor for the prognosis of HCC. The united signature could precisely identify unfavorable clinical outcome of HCC.

show abstract

Hepatocellular carcinoma in patients with chronic hepatitis C and cirrhosis in Denmark: A nationwide cohort study

Cited by 7 publications

References 49 publications

Real‐world evidence in hepatocellular carcinoma

Real‐world evidence in hepatocellular carcinoma

Hepatitis C virus genotype 3: clinical features, current and emerging viral inhibitors, future challenges

The Mechanism and Prognostic Value of DNA Polymerase δ Subunits in Hepatocellular Carcinoma: Implications for Precision Therapy

Contact Info

Product

Resources

About